Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie, Pfizer Jump in on Newly Launched Jnana Therapeutics’ $50 Million Funding Round

Jnana Therapeutics launched with a $50 million Series A financing. Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

Read More »

Keytruda Fails Phase III Stomach Cancer Study

Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Read More »

reMYND Forges 350M+ Euros Tie-Up With Novo Nordisk

Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

Read More »

Teva Cuts 14,000 Jobs in Massive Reorganization

Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.

Read More »

Regeneron, Sanofi Show Off Phase II Skin Cancer Data

Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.

Read More »

Daichi Sankyo Abandons Deal With Nektar Therapeutics After Drug Tanks in Europe

Daiichi Sankyo Europe GmbH informed Nektar Therapeutics that it was terminating a collaboration and licensing deal, which becomes effective Feb. 4, 2018. All rights and licenses that Daiichi acquired in the deal will revert to Nektar.

Read More »

J&J Tops Bioethics International Transparency Report

Johnson & Johnson topped the Bioethics International “Good Pharma Scorecard” for the second year in a row.

Read More »

Allergan Swoops in and Bags Troubled Repros Therapeutics

Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.

Read More »

265 Employees Affected as San Diego’s Dart NeuroScience Decides to Close Its Doors

Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.

Read More »

Genentech’s Hemlibra Data Wows at ASH

At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Read More »

bluebird, Celgene Tout ‘Unheard of’ Early-Stage Multiple Myeloma Data

Summit, NJ-based Celgene and Cambridge, Mass.-based bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

Read More »

‘Ground-breaking’ new drug gives hope in Huntington’s disease

Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.

Read More »

Fully Loaded With Nearly 500 Employees in Rockville, GlaxoSmithKline Chief Lays Out 2018 Goals

With one year of operations now under its belt since the grand opening, pharma giant GlaxoSmithKline has a bold future planned for its research and development facility in Maryland.

Read More »

Ex-Genentech Employees’ Denali Breaks 2017 IPO Records, Raises $250 Million

Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.

Read More »

Halozyme, Alexion Reach R&D Deal

San Diego’s Halozyme Therapeutics tied up a licensing agreement with Connecticut-based Alexion Pharmaceuticals that could net the company $680 million.

Read More »

Spark, Pfizer’s Gene Therapy Hemophilia B Drug Stuns in Trial

Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.

Read More »

Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen and Others

Obsidian Therapeutics officially launched with the completion of a Series A financing worth $49.5 million. Obsidian is focusing on immuno-oncology, and includes regulated cytokine cassettes to be used with CAR-T products.

Read More »

Depomed Pink Slips 40 Percent of Staff

Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.

Read More »

Idorsia Scores R&D Deal With Janssen Biotech

J&J’s Janssen Biotech entered into a collaboration deal with Idorsia to jointly develop and market aprocitentan for hypertension and any derivative compounds.

Read More »

Ultragenyx Stock Booms After Burosumab Continues to Impress in Phase III Study

Shares of Ultragenyx sharply climbed after the company announced positive results from its Phase III study of burosumab in adults with X-linked hypophosphatemia (XLH).

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!


Ad Right Bottom

Main Navigation